Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-9451 + peginterferon alfa-2a + ribavirin
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral (GS-9451, Ribavirin), Subcutaneous (peginterferon Alfa-2a)
01
Overview
**GS-9451 + peginterferon alfa-2a + ribavirin** is a three-drug combination investigated as antiviral therapy for chronic hepatitis C virus infection, principally genotype 1[1][3]. GS-9451 is a novel, reversible, noncovalent, small molecule inhibitor of the HCV nonstructural NS3/4a serine protease, showing potent activity in vitro and in early-phase clinical studies[1][3][5]. Peginterferon alfa-2a is a pegylated recombinant interferon that stimulates antiviral, immunomodulatory effects, and ribavirin is a nucleoside analog antiviral that inhibits viral replication. Combination therapy is intended to both directly inhibit HCV replication and stimulate host immune clearance, with improved sustained virologic response rates versus historic interferon regimens[2][4][6].
- Brand names
- Pegasys (peginterferon alfa-2a)
- Other names
- peginterferon alfa-2aribavirin
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on GS-9451 + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-9451 + peginterferon alfa-2a + ribavirin.